Skip to content
All Sections
Subscribe Now
80°F
Tuesday, July 30th 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
80°F
Tuesday, July 30th 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
Electric bills soarâ¡
Man killed in garage
Affordable housing coming to Midtown
Cancer rates drop
Olympics: How to watch ð¥
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aditxt, Inc.
< Previous
1
2
Next >
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
July 25, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
APLIF
OTC
TSX:APLI
Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing
July 17, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
EVFM
CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules
May 03, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
April 02, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
APLIF
TSX:APLI
Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications
January 30, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million
January 08, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
January 05, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement
January 02, 2024
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules
December 29, 2023
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally
December 12, 2023
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
EVFM
Aditxt, Inc. to Present at 8th Annual Dawson James Conference
October 06, 2023
From
Aditxt, Inc.
Via
GlobeNewswire
Tickers
ADTX
Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform
October 05, 2023
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023
September 08, 2023
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
September 06, 2023
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
August 31, 2023
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale
August 18, 2023
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
CORRECTING and REPLACING Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023
August 17, 2023
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt, Inc.’s Wholly-Owned Subsidiary Pearsanta, Inc. Looks to Expand Customer Base, Payor Access, and Genetic Testing with a Non-Binding Letter of Intent to Acquire Natural State Laboratories and Natural State Genomics
June 20, 2023
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome
May 05, 2023
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
April 20, 2023
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan
April 20, 2023
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Issues Shareholder Update
April 17, 2023
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Names Media Industry Veteran Maureen Connolly as Chief Content and Engagement Officer
March 08, 2023
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Retains Riverside Management Group as Advisor to Support Strategic M&A Driven Acquisitions by Subsidiary Pearsanta, Inc.
March 03, 2023
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Forms its Second Subsidiary, Pearsanta, Inc., to Accelerate the Growth of its AditxtScore™ Program and Appoints Healthcare Executive and Current Head of AditxtScore™ Anthony Voorhies to Serve as its President
February 14, 2023
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO
January 03, 2023
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt’s (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI™-100 in Preparation for Planned Psoriasis First-in-Human Trials
October 21, 2022
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt, Inc. (Nasdaq: ADTX) Announces Development and Publication of a Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection
October 12, 2022
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
FedEx Features AditxtScore™ Immune Monitoring Center and its Service in Richmond, VA, Highlighting the Importance of Quantifying Immune Health
October 07, 2022
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt, Inc. (NASDAQ: ADTX) Announces That it Has Regained Compliance with Nasdaq Listing Requirements
September 29, 2022
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close